Search

21-Sep-2012   IOTA InFarmatik Press Release     22-Feb-2011   IOTA announces KINOMED, a new partnership to accelerate protein kinase drug discovery Cambridge, UK / Odense, Denmark / Lund, Sweden, February 22, 2011     17-Aug-2009   New consortium to develop drugs for neglected tropical diseases     23-Apr-2008   IOTA announces SPR initiative with Beactica AB     21-Dec-2007   IOTA announces FBDD screening services     21-Dec-2007   IOTA announces collaboration with Vitas M-laboratory and new FBDD library:IOTA-Vitas 4000     5-Aug-2007   IOTA Pharmaceuticals established; research centers in the UK, the Netherlands, and India.     3-Aug-2007   IOTA announces FBDD Initiative with the VU University, Amsterdam     25-Sep-2007   IOTA announces first FBDD product: IOTA Diverse 1500         IOTA Pharmaceuticals has been established to bring you the tools and technologies for fragment-based drug discovery.   Our reagents are available without complex licences.   Our technologies are backed by established teams working daily with them in the laboratory.   Enter the IOTA world of drug discovery here.       IOTA has recently released a range of new products and services:   IOTA Diverse 1500   IOTA-Vitas 4000   FBDD Screening Services   [Press Release]       Built on expertise in the field of large pharma drug design, and supplemented by access to cost-effective chemistry, state-of-the-art medchem, and tailored fragment screening, we offer industry-leading fragment-based drug discovery capabilities.   IOTA has 4 intercalated discovery teams, focused on fragment design, fragment synthesis, fragment screening, and fragment-based lead discovery.   IOTA’s Design Labs are based in the IT-leading University city of Cambridge, UK. IOTA’s Synthesis Labs are located in Ahmedabad, in Gujarat, India. IOTA’s Screening and Lead Discovery Labs are based in Amsterdam, Holland.

Copyright © 2007 IOTA Pharmaceuticals  |   Site by Dots & Coms